Welcome to our dedicated page for Molina Hlthcare SEC filings (Ticker: MOH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Molina Healthcare, Inc. filings document the regulatory record for a managed healthcare company serving Medicaid, Medicare and state insurance marketplace programs. Its 8-K reports disclose operating results, premium revenue and earnings guidance, Regulation FD investor presentations, material agreements, direct financial obligations, impairment charges and senior unsecured note financing.
The company's proxy and governance filings cover annual meeting proposals, director and executive compensation matters, equity incentive plan authorization and amendments to charter or bylaw provisions such as stockholder special-meeting rights. The filing record also describes capital-structure terms, credit agreement covenants, risk-factor references and shareholder voting outcomes.
T. Rowe Price Associates, Inc. filed a Schedule 13G reporting beneficial ownership of 3,509,476 shares of Molina Healthcare, Inc. common stock, equal to 6.5% of the class as of 09/30/2025.
The firm reports sole voting power over 3,444,520 shares and sole dispositive power over 3,507,472 shares, with no shared voting or dispositive power. Filed in its capacity as an investment adviser, the statement affirms the holdings were acquired and are held in the ordinary course and not for changing or influencing control.
Molina Healthcare (MOH): AQR Capital Management, LLC and AQR Capital Management Holdings, LLC filed a Schedule 13G reporting beneficial ownership of 2,934,130 shares of Molina Healthcare common stock, representing 5.41% of the class as of the event date 09/30/2025.
The filing shows shared voting power over 2,934,130 shares and shared dispositive power over 2,934,130 shares, with no sole voting or dispositive power. The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Molina Healthcare reported softer profitability on higher revenue in Q3 2025. Total revenue reached $11.48 billion, up from $10.34 billion a year ago, led by premium revenue of $10.84 billion (up 12%). Net income fell to $79 million, or $1.51 per diluted share, from $326 million, or $5.65, as medical costs rose faster than premiums.
Margins compressed as medical costs accelerated. The consolidated medical care ratio was 92.6% versus 89.2% last year, reflecting a challenging cost trend, especially in Marketplace. The G&A ratio was 6.4% versus 6.5%, showing expense discipline. Interest expense rose to $49 million from $29 million alongside higher borrowings.
Balance sheet and capital actions were active. Long‑term debt increased to $3.66 billion from $2.92 billion, including new term loans. Operating cash flow for the first nine months was a use of $237 million. The company completed $1.0 billion of share repurchases year‑to‑date, including approximately 2.85 million shares for $500 million in Q3. Membership was 5.6 million at September 30, 2025. Molina closed the ConnectiCare acquisition for $350 million, adding goodwill and identifiable intangibles.
Molina Healthcare (MOH) filed an 8-K announcing it released its financial results for the third quarter ended September 30, 2025 and updated its full-year 2025 earnings guidance. The company provided these details in a press release attached as Exhibit 99.1.
This is a routine disclosure under Item 2.02, directing readers to the press release for the specific results and guidance figures.
The filing shows that Ronna Romney, a director of Molina Healthcare, Inc. (MOH), received an equity grant under the company’s 2025 Equity Incentive Plan on 10/01/2025. The award represents a quarterly portion of the director annual equity retainer of $220,000, with one quarter equal to $55,000. Based on the closing stock price of $192.79 on the grant date, the grant comprised 285 shares.
After the grant, the filing reports 17,416 shares beneficially owned by Ms. Romney, held indirectly through the Ronna Romney Revocable Trust. The Form 4 was signed by a power of attorney on 10/02/2025. The disclosure is a routine director equity compensation report and records the grant price and the indirect ownership vehicle.
T. Rowe Price Associates reported a beneficial ownership stake in Molina Healthcare Inc. totaling 2,207,124 shares, equal to 4.1% of the outstanding common stock. The filing shows the firm has sole voting power over 2,124,376 shares and sole dispositive power over 2,206,422 shares, with no shared voting or dispositive power.
The filing is submitted on Schedule 13G and classifies the filer as an investment adviser. The filer certifies the shares were acquired and are held in the ordinary course of business and states the position was not taken to change or influence control of the issuer, and the filer disclaims beneficial ownership in one section.
Capital Research Global Investors (CRGI) discloses beneficial ownership of 2,166,093 shares of Molina Healthcare common stock, representing 4.0% of 54,200,000 shares believed outstanding. CRGI reports sole voting power over 2,161,524 shares and sole dispositive power over 2,166,093 shares, and identifies itself as an investment adviser organized in Delaware filing under Rule 13d-1(b).
The filing states the position is held in the ordinary course of business and was not acquired to change or influence control of the issuer. Because the stake is under 5%, it is reported on Schedule 13G/A as a passive institutional holding, which signals notable institutional interest without indicating an active control campaign.
Molina Healthcare amended its existing credit facility to add a new Delayed Draw A-2 commitment of $500 million, creating a Term Loan A-2 that matures on August 12, 2027. The new tranche carries an applicable margin of 0.50% for base rate loans and 1.50% for SOFR-based loans and is substantially similar in other terms to the prior credit agreement.
The company states it will use the Term Loan A-2 proceeds to partially fund its previously authorized stock repurchase program as a temporary measure because of the timing of subsidiary dividends to the parent later this year. The amendment and related agreement are included as Exhibit 10.1, with certain schedules omitted from the public filing but available to the SEC upon request. This amendment creates a direct financial obligation under the Amended Credit Agreement.
Ronna Romney, a director of Molina Healthcare (MOH), filed a Form 4 reporting a sale of 700 shares of Molina Healthcare common stock on 08/06/2025 at a volume-weighted average selling price of $153.74 with individual sale prices reported in the range $153.43 to $154.32. The filing shows 17,131 shares are beneficially owned indirectly by the Ronna Romney Revocable Trust. The Form was filed by one reporting person and executed on behalf of Ms. Romney by Jeff D. Barlow under power of attorney on 08/08/2025.
The filing includes an explanatory note that the reported price is the VWAP for sales on the transaction date and offers to provide detailed per-price quantities to Commission staff on request. No derivative transactions are reported and the Form does not state a reason for the sale or explicitly indicate whether the sale was part of a Rule 10b5-1 plan.